Our Small-Cap Biopharma Firm Presents
Ocular Therapeutix detailed its outlook during the UBS Global Biopharma Conference in London.
You've reached your free article limit
You've read 0 of 1 free Pro articles.

On Tuesday, portfolio hoarding Ocular Therapeutix (OCUL) presented at the UBS Global Biopharma Conference 2026 in London, England.
The event was attended by more than 130 biopharma companies and more than 500 institutional investors. This is considered sort of a mid-tier investor conference, quite useful for unproven firms with a new yet to be commercialized product like Ocular. This is the inaugural conference in what is expected to be an annual series.
The event has been well-attended. It鈥檚 not a must-watch event for the broader market the way the JPMorgan Healthcare Conference in January is, but it is relevant enough for the companies presenting. Alice Nettleton of UBS Investment Bank asked the questions. Ocular President and CEO Pravin Dugel answered. Here are excerpts (I have picked out what I thought would be important to the portfolio) from Ocular’s presentation:
Intro: The company is called Ocular Therapeutix. We have a drug that has successfully completed a Phase III study. We have been able to show superiority versus an anti-VEGF for the first time ever. We have a result that has a very robust p-value of less than 0.0006, and we’re getting ready to submit for approval this quarter. We are on track to do that. The drug is called AXPAXLI. It’s a TKI. We believe that we’ll be the first and only proper maintenance drug. We have shown in this trial that this drug will last for a year in most patients. And unlike the other drugs that you know about that are bolus injections, and there’s a lot of them, whether they be generic or premium drugs, we believe that our drug will be the first drug that will be approved as a true maintenance drug.
Question: Following the recent competitor Phase III miss in wet AMD, there’s been some debate among investors around the potential read-through to AXPAXLI, given these drugs are both TKIs. Could you talk about the important differences and why you’re still confident in AXPAXLI?
Answer: I don’t necessarily enjoy speaking about other people or failures, but we absolutely predicted that this was going to happen 2.5 years ago. We told you exactly what was going to happen with EyePoint. We said that their TKI was an inferior TKI as well as VEGF suppression is concerned. We know that from a lot of studies that have already been done that we have cited. We said that their delivery system was inferior. Very, very importantly, and this is extremely important, we said that they had really put no thought into patient selection, and patient selection was absolutely key. We have spent a great deal of time, a great deal of thought selecting the proper patients in a bespoke manner for each study, which they did not do, and we can talk about that in detail.
Question: You’ve obviously had a successful SOL-1 trial, and you’re hoping to submit your NDA soon or perhaps that’s already in process. Can you provide an update on that?
Answer: What the FDA has said in a very consistent manner is that there is an option for single trial submission that has been there for decades. And their criteria for that, the evidentiary standards, as they say for that has not changed at all, has not changed at all. There are 2 evidentiary standards prior to the card turn, and there are 2 evidentiary standards after the card turn.
Prior to the card turn, first of all, the study has to be well masked, and that’s really important. And this is where pretty much everybody other than us doesn’t qualify because well masked means that there can’t be a sham arm. The FDA does not consider sham to be proper masking. Sham is when you touch the eye with the hub of a syringe, and patients know when the drug is coming in or not. Because it’s a subjective endpoint, which is visual acuity, the FDA feels that that’s not a proper masking. So that’s one evidentiary standard. The second is that it has to be properly powered. Now we’ve met both of those because we have a SPA, or a Special Protocol Agreement, with the FDA based on the SOL-1 study.
After the card turn, there are 2 other evidentiary standards. The first one is that it has to have a p-value of less than 0.001. Our study has a p-value of less than 0.0006. And the second is that you have to be able to supply at least 300 patients who’ve been exposed to the drug for safety purposes at the time of submission. So immediately following our card turn, knowing that we had a p-value that checked the box, we had a Type C meeting immediately in May. The card turn was in the middle of February. And we have a clear path forward for single trial submission officially. We said that we’re going to have our pre-NDA meeting in the third quarter of this year. We did. It was a very successful pre-NDA meeting. And we said that we would be submitting the NDA in the fourth quarter of this year, and we’re on track to do that.
Question: So once you submit the NDA, which sounds like it’s on track, what are the next updates that investors will receive from you about how that’s going? And if it’s approved, when could AXPAXLI launch by your best guess in the U.S.?
Answer: As far as the track of the filing is concerned, realize that we’re in (on an) accelerated track, right? We officially have a 505(b)(2), meaning that both components of the drugs have been previously FDA approved independently. So that saves us at least 2 months on the front end. We expect this filing to be very efficient also on the back end because we have a SPA agreement, right? So we expect the filing to be very efficient. We just haven’t given you time lines as yet, but we are on an accelerated pathway.
Question: So, you’re running another trial with AXPAXLI, as you said, in nonproliferative diabetic retinopathy called HELIOS-3. During your recent earnings call, I think you noted that enrollment is progressing well. So if you could provide an update on that? And could you talk about how important patient selection is in this indication as in wet AMD with your drug?
Answer: As you can imagine, in diabetic retinopathy, there’s a window. If patients are enrolled who don’t have enough disease, one may not be able to show a delta. If patients are enrolled with too severe disease, one may not be able to change the course of the disease. So although there’s no competition, we could easily finish enrollment much, much quicker. We’re being very, very, very careful about patient selection in this disease, as we have been with wet macular degeneration.
It’s important to say that we’re not just enrolling for diabetic retinopathy. We’re enrolling for diabetic retinopathy and for noncentral-involved diabetic macular edema. Our expectation is that we will have a label that will encompass all of diabetic retinal disease, so diabetic retinopathy and diabetic macular edema. And our expectation is that we will not have to do another study again for diabetic retinal disease at all, and that label will be broad enough to encompass all of diabetic retinal diseases.
Other News
Ocular Therapeutix (OCUL)
On Tuesday, analyst Yi Chen of HC Wainwright reiterated his “buy” rating on OCUL as well as his $28 target price. Chen is rated at 0.5 stars out of five by TipRanks. Over the past two years, he has compiled a success rate of 33%, while generating an average return of -3.8%.
SoFi Technologies (SOFI)
On Tuesday, Bullish (BLSH) and Equiniti announced that DRW, Flow Traders, portfolio holding SoFi (SOFI) and Superstate have joined the Issuer Token Coalition, the industry working group convened to advance standards for issuer tokens. These additions bring the coalition to 12 firms in less than two months since the launch. The coalition’s next phase of work will focus on defining standards and specific collaboration work streams including liquidity mechanics, standards and tech architecture, and building out a commercially viable ecosystem to support issuer tokens.
Tuesday’s Intention vs Actual Trade
Intention: Purchase 30 shares of ONDS at or close to the last sale of $4.65
Actual trade: Bought 30 shares of ONDS at $4.43
Wednesday’s Intentions
Sell 5 shares of RKLB at or close to the last sale of $54.07
Purchase 15 shares of SOFI at or close to the last sale of $14.22
Purchase 25 shares of OCUL at or close to the last sale of $6.00
Current Positions
Long 80 shares of (ASPN) at $5.0263. Target price: $8. Last sale: $4.93.
Long 100 shares of (EVLV) at $4.7679. Target price: $7.50. Last sale: $3.97.
Long 200 shares of (OCUL) at $7.7263. Target price: $10. Last sale: $6.00.
Long 400 shares of (ONDS) at $7.061. Target price: $10. Last sale: $4.47.
Long 100 shares of (PTON) at $5.2708. Target price: $9. Last sale: $5.29.
Long 15 shares of (RKLB) at $49.292. Target price $84. Last sale: $54.07.
Long 150 shares of (SOFI) at $15.947. Target price: $24. Last sale: $14.22.
Cash: $216.93.
Portfolio value: $7,481.48, -25.2% from inception on March 24.
At the time of publication, Guilfoyle was long ASPN, EVLV, OCUL, ONDS, PTON, RKLB and SOFI.
